iShares Biotechnology ETF
The iShares Biotechnology ETF (IBB) rose 23.1% through Oct. 23, driven by drug milestones. Merck and Moderna reported positive Phase 3 trial data for intismeran autogene. Roche's Enspryng gained FDA approval for thyroid eye disease. Eli Lilly plans to submit a weight-loss drug for FDA review in early 2027. IBB's expense ratio is 0.44%, while SPDR S&P Biotech ETF (XBI) has a 0.35% expense ratio.
iShares Biotechnology ETF (IBB) sold $287.9M in stocks on Thursday, including Gilead Sciences (GILD) for $23.6M, Amgen (AMGN) for $22.1M, and Vertex Pharmaceuticals (VRTX) for $21.8M. IBB's assets under management stand at $10.55B. The fund holds 227 stocks with a 21.75% year-to-date return.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IBB (iShares Biotechnology ETF). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent IBB coverage spans market movers and financial news.
ETF likely to continue gaining as biotech trial data and approvals boost sector sentiment.
iShares Biotechnology ETF (IBB) sold $287.9M in stocks on Thursday, including Gilead Sciences (GILD) for $23.6M, Amgen (AMGN) for $22.1M, and Vertex Pharmaceuticals (VRTX) for $21.8M. IBB's assets under management stand at $10.55B. The fund holds 227 stocks with a 21.75% year-to-date return.
AlphAI scores every news story that mentions IBB with an AI model for sentiment and relevance, and aggregates insider trades from iShares Biotechnology ETF's SEC EDGAR Form 4 filings. Figures refresh continuously.
The iShares Biotechnology ETF (IBB) rose 23.1% through Oct. 23, driven by drug milestones. Merck and Moderna reported positive Phase 3 trial data for intismeran autogene. Roche's Enspryng gained FDA approval for thyroid eye disease. Eli Lilly plans to submit a weight-loss drug for FDA review in early 2027. IBB's expense ratio is 0.44%, while SPDR S&P Biotech ETF (XBI) has a 0.35% expense ratio.
2 min readiShares Biotechnology ETF (IBB) sold $287.9M in stocks on Thursday, including Gilead Sciences (GILD) for $23.6M, Amgen (AMGN) for $22.1M, and Vertex Pharmaceuticals (VRTX) for $21.8M. IBB's assets under management stand at $10.55B. The fund holds 227 stocks with a 21.75% year-to-date return.
1 min read
